Al Mazida Fauzil Aishaqeena, Fahriza Abid Sonia, Achmad Guntur Hermawan Suryo Adji, Rislan Faiz Muhammad, Basyar Adnani, Ardian Rizal, Djanggan Sargowo
Cardiometabolic syndrome, or often referred to as metabolic syndrome, is a concurrent metabolic instability that increases the risk of obesity, hyperlipidemia, diabetes, hypertension, atherosclerosis, and other end stages of disease. Causes of cardiometabolic syndrome include hypertension, insulin resistance, obesity, hypercholesterolemia, and progressive cardiovascular disease. The main pathophysiology are in excess too much release of free fatty acids (FFA) from adiposal tissue, cause of risk factors for CMS include a sedentary lifestyle and unhealthy habits that leads a condition that make some correlation between obesity and type 2 diabetes (T2DM), female, divorce and an increase in Body Mass Index (BMI), into plasma and elevated plasma concentration of free fatty acid can reduce insulin ability to stimulate glucose im muscle and inhibit production glucose of hepar, unwanted of intracellular fatty acids increased the production of reaction of oxygen species (ROS). Peptide Polysaccharide β-D-Glucans in Ganoderma lucidum mycelia was also reported to have anti-oxidant, anti-tumor, anti-inflammatory, anti-hypertensive, antihistamine, and anti-hepatotoxic results. This study by true experimental with double blinded using randomized control trial. This study obtained 62 patients with CMS, Then the 62 patients were divided into two groups, the PsP group and the placebo group. The result Polysaccharide Peptides from Ganoderma lucidum mycelia extract for 60 days can increase levels of SOD significantly (P 0.00); reduce levels of MDA (P 0.004), fasting blood glucose and HbA1C not significantly, P 0.930 and P 0.053; however, descriptively, the results showed a decrease so is still possible for Ganoderma lucidum extract to have an effect as reducing blood glucose profile markers in patients with the cardiometabolic syndrome. The conclusion is that Ganoderma lucidum can act as an antioxidant as evidenced by the significantly decreased in MDA and significantly increased in SOD in the therapy group. Whereas Ganoderma Lucidum acts as an antihyperglycemic proven descriptively to reduce fasting blood glucose and HbA1C levels. © 2025 American Institute of Physics Inc.. All rights reserved.
Master of Biomedical Science, Faculty of Medicine, Universitas Brawijaya, Jl. Veteran, Malang, 65145, Indonesia; Cardiology Department, Faculty of Medicine, Universitas Brawijaya, Jl. Veteran, Malang, 65145, Indonesia
